
Metabolomics as a biomarker technology in pharmaceutical R&D
Virtual event
Metabolomics as a biomarker technology in pharmaceutical R&D
May 24th, 2022
4:00 pm CET (10:00 am EST)
Registration
Participation is free of charge, but registration is required.
By entering your contact details, you agree to our Privacy policy.
Speakers

Isabella Gashaw, PhD
Principal Clinical Biomarker Lead, Cardiometabolism, Boehringer Ingelheim, Germany

Anna Maria Halama, PhD
Assistant Professor of Research in Physiology and Biophysics, Weill Cornell Medicine, Qatar

Stefan Ledinger, MA BSc
Director | Business development
biocrates life sciences ag
During this event you will learn
- Why better means of patient stratification are needed
- Why metabolomics is a promising technology for biomarker research in pharmaceutical R&D
- How metabolomics could help identify and overcome resistance mechanisms
Agenda
4:00 pm (10:00 am EST)
Introduction: Why and how does metabolomics contribute to better therapies?
Stefan Ledinger, MA BSc
4:10 pm (10:10 am EST)
Multi-omics approaches for biomarker development in the pharmaceutical industry
Isabella Gashaw, PhD
4:40 pm (10:40 am EST)
Advancing cancer treatment by targeting dysregulated metabolism – A roadmap
Anna Maria Halama, PhDPhD
5:10 pm (11:10 am EST)
Wrap up
Stefan Ledinger, MA BSc
2023 © biocrates life sciences ag